See more : China Quanjude(Group) Co.,Ltd. (002186.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Chongqing Sansheng Industrial Co.,Ltd. (002742.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chongqing Sansheng Industrial Co.,Ltd., a leading company in the Construction Materials industry within the Basic Materials sector.
- GlobalData Plc (DATA.L) Income Statement Analysis – Financial Results
- PropTech Investment Corporation II (PTICW) Income Statement Analysis – Financial Results
- Alabama Power Company (ALP-PQ) Income Statement Analysis – Financial Results
- LivePerson, Inc. (LPSN.TA) Income Statement Analysis – Financial Results
- Belite Bio, Inc (BLTE) Income Statement Analysis – Financial Results
Chongqing Sansheng Industrial Co.,Ltd. (002742.SZ)
About Chongqing Sansheng Industrial Co.,Ltd.
Chongqing Sansheng Industrial Co.,Ltd. engages in the research and development, production, and sale of building materials and chemicals in China. The company offers commercial concrete, water reducing agents, and expansion agents for industrial and civil buildings, highways, railways, bridges, tunnels, airports, water conservancy and hydropower, etc.; and sulfuric acid for the production of chemical fertilizers, chemical, light industry, textile, steel, water reducer, and other non-fertilizer acid enterprises. It also provides pharmaceutical products comprising intermediates, such as procaine hydrochloride, cefoxitin intermediate, chloramphenicol intermediate, aztreonam intermediate, orlistat intermediate, etc., which are used in antibiotic drugs, anti-hepatitis C drugs, diabetes medicines, benzathine penicillin and cefoxitin, procaine penicillin, and cosmetics; API products, including acetaminophen, cloperidine hydrochloride, levofloxacin mesylate, benoate, procaine hydrochloride, diphenhydramine hydrochloride, etc.; and preparation products, such as compound paracetamol diphenhydramine, cloperidine hydrochloride, clarithromycin sustained-release, diclofenac sodium enteric-coated, acetaminophen, famotidine tablets, etc., which are used in antipyretic and analgesic, antiviral, antibacterial, cough, allergy, local anesthesia, etc., as well as famotidine, diclofenac sodium, nifedipine, acetaminophen, furosemide, and norfloxacin drugs for clinical needs. The company was formerly known as Chongqing Sansheng Special Building Materials Co., Ltd. and changed its name to Chongqing Sansheng Industrial Co.,Ltd. in October 2016. The company was founded in 2002 and is based in Chongqing, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.03B | 2.08B | 2.49B | 2.55B | 3.18B | 2.87B | 1.90B | 1.51B | 1.41B | 1.27B | 1.17B | 1.06B | 847.78M |
Cost of Revenue | 1.65B | 1.76B | 2.08B | 1.96B | 2.54B | 2.22B | 1.45B | 1.15B | 1.11B | 1.03B | 949.46M | 847.15M | 674.83M |
Gross Profit | 380.04M | 317.19M | 405.41M | 589.00M | 637.83M | 646.59M | 449.62M | 366.10M | 305.27M | 245.03M | 224.51M | 214.58M | 172.95M |
Gross Profit Ratio | 18.72% | 15.27% | 16.29% | 23.10% | 20.06% | 22.57% | 23.63% | 24.20% | 21.64% | 19.28% | 19.12% | 20.21% | 20.40% |
Research & Development | 17.37M | 14.88M | 27.50M | 31.83M | 34.10M | 34.05M | 25.21M | 14.99M | 9.08M | 7.39M | 0.00 | 0.00 | 0.00 |
General & Administrative | 80.84M | 63.89M | 93.49M | 96.32M | 91.35M | 84.48M | 54.89M | 41.01M | 24.29M | 18.25M | 18.85M | 18.16M | 18.26M |
Selling & Marketing | 60.11M | 47.83M | 40.45M | 59.84M | 43.07M | 35.62M | 39.01M | 33.01M | 26.71M | 26.62M | 26.22M | 27.42M | 18.44M |
SG&A | 140.95M | 111.71M | 133.95M | 156.17M | 134.42M | 120.09M | 93.90M | 74.02M | 51.00M | 44.87M | 45.07M | 45.58M | 36.70M |
Other Expenses | 498.08M | 140.53M | 157.11M | 138.23M | 134.04M | -2.47M | 4.35M | 39.13M | 30.24M | 892.91K | 37.18M | 16.77M | 10.78M |
Operating Expenses | 656.40M | 267.13M | 318.55M | 326.23M | 302.56M | 283.79M | 228.55M | 167.25M | 119.64M | 85.77M | 82.19M | 81.40M | 61.07M |
Cost & Expenses | 2.31B | 2.03B | 2.40B | 2.29B | 2.84B | 2.50B | 1.68B | 1.31B | 1.23B | 1.11B | 1.03B | 928.55M | 735.90M |
Interest Income | 964.25K | 2.00M | 8.32M | 11.57M | 11.08M | 11.56M | 1.87M | 1.53M | 2.34M | 1.06M | 447.17K | 577.46K | 98.84K |
Interest Expense | 169.22M | 157.58M | 161.03M | 152.22M | 137.99M | 138.43M | 66.25M | 36.91M | 29.90M | 34.66M | 22.66M | 13.57M | 10.37M |
Depreciation & Amortization | 126.49M | 138.09M | 156.45M | 167.12M | 172.07M | 157.31M | 131.17M | 83.04M | 68.66M | 64.40M | 47.55M | 41.64M | 41.53M |
EBITDA | -26.59M | 70.03M | -18.93M | 436.63M | 473.82M | 459.05M | 413.37M | 264.81M | 242.28M | 218.66M | 151.46M | 145.58M | 154.61M |
EBITDA Ratio | -1.31% | 6.48% | 7.77% | 16.58% | 15.82% | 18.10% | 21.70% | 18.41% | 18.23% | 17.58% | 17.09% | 16.80% | 18.13% |
Operating Income | -276.35M | 2.36M | 44.18M | 262.76M | 338.00M | 174.16M | 210.67M | 141.24M | 143.61M | 118.70M | 109.13M | 117.27M | 102.49M |
Operating Income Ratio | -13.61% | 0.11% | 1.77% | 10.31% | 10.63% | 6.08% | 11.07% | 9.34% | 10.18% | 9.34% | 9.30% | 11.04% | 12.09% |
Total Other Income/Expenses | -51.59M | -242.69M | -386.73M | -149.63M | -167.41M | -2.47M | 4.35M | -36.24M | 108.95K | 892.91K | 12.31M | 3.37M | 232.88K |
Income Before Tax | -327.94M | -240.33M | -342.55M | 113.13M | 170.59M | 171.69M | 215.02M | 143.49M | 143.72M | 119.59M | 121.44M | 120.64M | 102.72M |
Income Before Tax Ratio | -16.15% | -11.57% | -13.76% | 4.44% | 5.36% | 5.99% | 11.30% | 9.49% | 10.19% | 9.41% | 10.34% | 11.36% | 12.12% |
Income Tax Expense | 81.37M | 51.26M | 18.28M | 28.66M | 25.43M | 31.17M | 25.28M | 22.97M | 20.47M | 18.37M | 19.10M | 18.16M | 15.49M |
Net Income | -452.05M | -291.59M | -360.84M | 73.44M | 124.84M | 110.84M | 180.33M | 117.91M | 121.76M | 101.06M | 102.55M | 102.48M | 87.23M |
Net Income Ratio | -22.27% | -14.04% | -14.50% | 2.88% | 3.93% | 3.87% | 9.48% | 7.79% | 8.63% | 7.95% | 8.74% | 9.65% | 10.29% |
EPS | -1.05 | -0.67 | -0.84 | 0.17 | 0.29 | 0.26 | 0.42 | 0.27 | 0.30 | 0.31 | 0.32 | 0.32 | 0.27 |
EPS Diluted | -1.05 | -0.67 | -0.84 | 0.17 | 0.29 | 0.26 | 0.42 | 0.27 | 0.30 | 0.31 | 0.32 | 0.32 | 0.27 |
Weighted Avg Shares Out | 430.52M | 432.00M | 432.00M | 432.00M | 432.00M | 431.95M | 429.36M | 432.00M | 412.75M | 322.54M | 324.93M | 324.72M | 324.42M |
Weighted Avg Shares Out (Dil) | 430.52M | 432.00M | 432.00M | 432.00M | 432.00M | 431.95M | 429.36M | 436.72M | 412.75M | 326.01M | 324.98M | 324.76M | 324.42M |
Source: https://incomestatements.info
Category: Stock Reports